Vivek Subbiah: Proud to welcome Mary Crowley Cancer Research to SCRI
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared a post on X:
“Exciting News!
So thrilled to announce a significant milestone for our early-phase drug development program at Sarah Cannon Research Institute (SCRI).
We are proud to welcome Mary Crowley Cancer Research, a leader in early-phase clinical research based in Dallas, Texas, to our family.
This strategic partnership enhances our ability to provide cutting-edge clinical trials and innovative treatments to patients in North Texas, right in their communities.
Together, we are committed to advancing cancer research and bringing hope to more patients through groundbreaking therapies.
Here’s to a future filled with innovation and improved patient outcomes!”
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.
He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
More posts featuring Vivek Subbiah.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023